In our research, we have detected mood-congruent attentional biases for sad and angry faces in experimentally induced sadness (Isaac et al., 2012) . This supports the hypothesis that human faces do indeed have "privileged access" to the affective network even at the transient phase of experimentally putting healthy participants into a sad mood state (De Houwer and Hermans, 1994) . Additionally, Bediou et al. (2012) focused upon additional groups of interest for risk evaluation such as unaffected siblings of Schizophrenia patients and present the means by which medication status may modulate processing of valenced faces. This latter point is neglected too often and it remains especially important to consider due to the role of antidepressant treatment in modulating amygdala response to positive or happy faces (Norbury et al., 2009) .
The objective of this commentary is to discuss the implications of Bediou et al.'s (2012) article. In summary, they conclude that facial emotion processing is indeed impaired in subjects exhibiting a variety of both psychiatric and neurological disorders. The faceemotion impairments appear to be both characteristic and specific to each disease. One can speculate that both the prevalence and specificity of face processing differences across such diseases can be employed as a potential biomarker that may be used to perform differential diagnoses, treatment outcome measurements as well as treatment response predictions. Unquestionably, this idea is bound to stimulate debate among researchers and clinicians alike. Much effort has gone into the neural network of faceemotion processing (Kanwisher et al., 1997; Haxby et al., 2000) , face-specific neurophysiology (Bentin et al., 1996) , computational modeling of face processing (Wallraven et al., 2005) , the mechanics that underlie experience dependent face processing such as featural vs. configural strategies (Yin, 1969) , and the developmental process of Bediou, B., Brunelin, J., d'Amato, T., Fecteau, S., Saoud, M., Hénaff, M., and Salmon, P. K. (2012) . Front. Psychol. 3:98. doi: 10.3389/fpsyg.2012.00098 This commentary highlights key points presented by Bediou et al. (2012) in Frontiers in Psychology. The authors have provided a foundation upon which to investigate face-emotion processing as a biomarker for both psychological and neurological diseases. To date, Bediou et al. (2012) are the first to provide a comprehensive analysis of the unique deficits in face-emotion processing associated with a wide range of diseases including but not limited to neurodegenerative diseases, mood disorders, psychopathology, and neurodevelopment disorders.
Recently there has been considerable interest in face-related research spanning various disciplines from psychology, neurology, and computational science. Moreover, face-emotion processing research has taken center stage in affective neuroscience leading researchers to investigate the complex relationship between disease, brain, cognition, behavior, and emotion as it relates to impairments in the processing of human faces at various stages of structural encoding, identification and familiarity, emotion recognition, and semantic retrieval pertaining to specific known faces. Bediou et al. (2012) present data from their previous work on face processing drawing from:
• Parkinson's disease, • fronto-temporal dementia, • mild cognitive impairment, • Alzheimer's disease, • major depression, and schizophrenia. face expertise (Gauthier and Nelson, 2001) . Notably, face-emotion processing deficit extends to populations beyond those studied by Bediou et al. (2012) . Advancements in face and emotion processing science have resulted in specific neurophysiological markers such as the P100 (initial visual processing of faces), N170 (structural encoding of facial features), N250 (decoding emotional content), and N450 (semantic retrieval for familiar faces). Impaired face-emotion processing extends to other pathologies such as social anxiety (Lange et al., 2011 ), Autism (Pierce et al., 2001 , and Williams Syndrome: a rare genetic disorder (Isaac and Lincoln, 2011) as well as traumatic brain injury (Valentine et al., 2006) . Interestingly, the various deficits often implicate specific brain regions as in lesion to the fusiform gyri and facial agnosia (Behrmann et al., 1994) or an enlarged amygdala and attenuated response to angry faces in Williams Syndrome (Golarai et al., 2010) and thus the connection is made between brain, behavior, and emotion stemming from faulty face processing. Thanks to the outstanding research and clinical advancements in this field, high prevalence, and relevance of face-emotion anomalies in a vast number of special populations has been established. It is proposed that face processing deficits be employed as both a biomarker for differential diagnosis and as a treatment outcome measurement. Furthermore, it is suggested that treatment response prediction shall become the ultimate goal of face-emotion science.
The question is where do we go from here? The next lines of enquiry may ask the following questions:
• How can specific face-emotion deficits aid in differential diagnosis? • How can face-specific deficits inform us about treatment outcome and treatment response? Such efforts are already underway. For example, studies examining the effectiveness of modifying facial cognitive biases in anxiety disorders have demonstrated that re-training such biases and improving cognitive control reduces anxiety level (MacLeod et al., 2002; Wadlinger and Isaacowitz, 2008) . Do certain patients suffer from temporal deficits concerning emotional faces despite successful treatment as is the case of remitted depression and sustained working memory disengagement deficits for angry faces (Isaac et al., submitted) ? Do patients activate control centers more variably over time compared to non-patients? Is it a matter of spatial magnitude whereby patients activate control centers to a lesser degree or more diffusely than controls (e.g., PFC/ ACC)? What vulnerabilities exist at the prodromal stage of disease that can possibly be ameliorated? Importantly, how can this research guide the clinical process to improve patient quality of life?
For instance, in schizophrenia research, we are now armed with the knowledge that abnormalities in late-stage feature decoding exist and can potentially underlie emotion identification deficits in this disorder (Wynn et al., 2008) . This indeed is a potential biomarker of underlying facial affect deficits in schizophrenia and it may very well be associated with the social cognitive deficits observed in schizophrenia. However, questions remain as to how facial-decoding abnormalities can explain clinical features such as paranoia and how this information can facilitate the development of new treatments that enhance social functioning in schizophrenia, depression, and other patient populations that may
